Comparison of in-stent restenosis and postprocedural mTICI grade between administration of GP IIb/IIIa inhibitors and no administration of GP IIb/IIIa inhibitors
| GP IIb/IIIa Inhibitors | P Value | ||
|---|---|---|---|
| Yes | No | ||
| ISR at discharge (yes) (%) | 0/16 (0) | 3/3 (50.0) | .013a |
| ISR at 3 mo (yes) (%) | 2/9 (18.2) | 4/1 (80.0) | .036a |
| Postprocedural mTICI grade (0–2a/2b–3) (%) | 2/16 (11.1/88.9) | 3/6 (33.3/66.7) | .295 |
| Overall hemorrhagic transformation (yes) (%) | 3/15 (16.7) | 4/5 (44.4) | .175 |
| Symptomatic ICH (yes) (%) | 1/17 (5.6) | 2/7 (22.2) | .250 |
| mRS at 3 mo 0–2 (%) | 8/18 (44.4) | 0/9 (0) | .026a |
| mRS at 6 mo 0–2 (%) | 9/18 (50.0) | 2/9 (22.2) | .231 |
| mRS at 12 mo 0–2 (%) | 9/18 (50.0) | 2/9 (22.2) | .231 |
| Mortality at 3 mo (%) | 3/15 (16.7) | 4/5 (44.4) | .175 |
| Mortality at 6 mo (%) | 4/14 (22.2) | 4/5 (44.4) | .375 |
| Mortality at 12 mo (%) | 4/14 (22.2) | 4/5 (44.4) | .375 |
Note:—GP indicates glycoprotein.
↵a Significant.